Contributed By Walder Wyss Ltd
It is prohibited to grant, offer or promise material benefits to persons who prescribe or dispense medicines or to the organisations that employ them and for such persons or organisations to solicit or accept such material benefits. However, material benefits of modest value that are related to medical or pharmaceutical practice as well as commercially and economically justified discounts that directly reflect on the price are permitted (Article 33 HMG). Such material benefits of modest value must not exceed CHF300 per healthcare professional or healthcare organisation and per year.
However, pharmaceutical companies may provide financial or other support to healthcare organisations for research or other services in the healthcare sector, provided that such support is limited to research or other services in healthcare, that it is set down in writing and that the relevant documents are available at the pharmaceutical company. Pharmaceutical companies must, however, fully disclose all pecuniary benefits that they grant (rules 222 and 23 et seqq. Pharma Cooperation Code).